A股異動 | 核酸檢測概念股普漲 廣東多個城市開展大規模核酸檢測
格隆匯6月7日丨核酸檢測概念股普漲,華大基因漲逾5%,萬孚生物漲4.73%。6月6日0-24時,廣東省新增4例本土確診病例,廣州報吿3例,深圳報吿1例;另有本土無症狀感染者轉確診病例1例,廣州報吿。新增2例本土無症狀感染者,廣州報吿1例,湛江報吿1例。廣州市南沙區、增城區、從化區、花都區5日發佈通吿,對全區户籍人口、來穗人員開展全員核酸檢測工作。至此,全員核酸檢測工作已覆蓋廣州全市11區。此外,繼龍崗、鹽田之後,深圳福田昨日起全員檢測,計劃177萬人三天檢完。中山市自6日至10日將對全市市民(含户籍人口、外來人口)開展大規模核酸檢測工作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.